合成了一系列香豆素-呋喃并[2,3-d]嘧啶酮杂化衍生物,并通过HR-MS、1 H NMR和13 C NMR进行了表征。所有合成的化合物均在体外评估了对肝癌(HepG2)和宫颈癌(Hela)细胞系的抗增殖活性,结果表明大多数化合物均表现出有效的抗肿瘤活性。此外,化合物3i、8d和8i被选择诱导HepG2细胞凋亡,并且表现出显着的浓度依赖性。进一步采用Transwell迁移实验检测了最强效的化合物8i,结果显示8i能够显着抑制HepG2细胞的迁移和侵袭。此外,激酶活性测定表明,化合物8i可能是一种多靶点抑制剂,在1μmol/L浓度下,8i对RON、ABL、GSK3α等10种不同激酶的抑制率为40-20%。同时,分子对接研究揭示了化合物3i、8d和8i与激酶受体d'origin nantais(RON)可能的结合模式。根据 3D-QSAR 研究建立了比较分子场分析 (CoMFA) 模型,该模型引导我们在呋喃[2
Coumarin–furo[2,3-d]pyrimidone hybrid molecules targeting human liver cancer cells: synthesis, anticancer effect, EGFR inhibition and molecular docking studies
作者:Tianshuai Wang、Yumeng Gao、Fengxu Wu、Lun Luo、Junkai Ma、Yanggen Hu
DOI:10.1039/d3md00668a
日期:——
inhibition of the EGFR enzymatic activity with IC50 = 1.53 μM and 90% inhibition at 10 μM concentration. In silico investigation predicts the possibility of direct binding between the new coumarin–furo[2,3-d]pyrimidone hybrid molecules and the EGFR. The results suggest that coumarin–furo[2,3-d]pyrimidone hybrid molecules are potential antitumor agentstargeting human liver cancer cells.
报道了一些香豆素-呋喃并[2,3- d ]嘧啶酮杂化分子的设计、合成和抗肿瘤活性研究。在体外,使用 HepG2 细胞研究6a-n和10a-n的细胞毒性。结果表明,通过酰肼连接体将呋喃嘧啶酮支架与香豆素偶联可以有效提高它们的协同抗癌活性。香豆素-呋喃并[2,3- d ]嘧啶酮组合10a对HepG2细胞表现出显着的抑制活性,IC 50 = 7.72 ± 1.56 μM,优于吉非替尼和索拉非尼。值得一提的是,香豆素-呋喃并[2,3- d ]嘧啶酮组合10a对EGFR酶活性表现出优异的抑制作用,IC 50 = 1.53 μM,在10 μM浓度下抑制率为90%。计算机研究预测新的香豆素-呋喃并[2,3- d ]嘧啶酮杂合分子与 EGFR 之间直接结合的可能性。结果表明,香豆素-呋喃并[2,3- d ]嘧啶酮杂合分子是针对人类肝癌细胞的潜在抗肿瘤剂。
The carbodiimides 2, obtained from aza-Wittig reactions of iminophosphorane 1 with aromatic isocyanates, reacted with ammonia to give ethyl 3,4-dihydro-6-methyl-4-oxo-2-arylamino-furo[2,3-d]pyrimidine-5-carboxylate 3. Further reaction of 3 with POCl3 and various amines generated ethyl 4-alkylamino-2-arylamino-6-methyl-furo[2,3-d]pyrimidine-5-carboxylate 5 in good yields. Their structures were confirmed by H-1 NMR, EI-Ms, IR and elemental analysis. Compound 5b was further analyzed by single crystal X-ray diffraction. Compound 5 exhibited cytotoxicity against two lung cancer cell lines. For example, compound 5a showed the best inhibition activities against A459 with IC50 0.8 mu M. (C) 2010 Elsevier Ltd. All rights reserved.